Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient

This real-world study is examining how stage IIIB/C–IV non-small cell lung cancer (NSCLC) patients fare when treated with platinum-based chemotherapy followed by high-dose radiation therapy and a drug called tislelizumab (an immunotherapy). The aim is to understand how this combination works in everyday clinical practice. **You may be eligible if...** - You are 18–75 years old with stage IIIB/C or stage IV non-squamous NSCLC confirmed by tissue or cell testing - You do not have EGFR, ALK, BRAF, ROS1, RET, or MET gene mutations — or targeted therapy has stopped working - You are in reasonably good health (ECOG 0–2) **You may NOT be eligible if...** - You have uncontrolled autoimmune disease - You have had significant immune reactions (e.g., inflammation of the lungs, heart, or thyroid) in the past 6 months that haven't stabilized - You have another type of cancer concurrently Talk to your doctor to see if this trial is right for you.